A phase I/II study of sunitinib and dacarbazine in patients with metastatic melanoma.

Trial Profile

A phase I/II study of sunitinib and dacarbazine in patients with metastatic melanoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2011

At a glance

  • Drugs Dacarbazine; Sunitinib
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Feb 2011 Planned end date changed from 1 Jun 2008 to 1 Jun 2007 as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov, last updated 28 Jan 2009.
    • 28 Jan 2009 Planned patient numbers (11) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top